William Rice: Yeah, I’ll start and then Dr. Bejar can come in. Thanks John, for coming on. So as we look at the patients being treated with monotherapy, clearly we want to enrich for certain of these populations. The ones that Dr. Bejar had mentioned, those that had failed prior FLT3 inhibitor, those have TP53 mutations. Now that we’ve seen some of these data with RAS, we’ll ask the investigators if we can try to find patients more like that and hope to get enough of these patients to be able to go to the FDA and say, Hey, there’s a real signal here. We’d like to move forward for the accelerated approval. But I also want to emphasize the doublet is very important for us because showing that your drug works well and is well tolerated in combination with venetoclax, that’s what’s going to launch us into two different pathways.
One is it’s going to position us for the triplet and to go towards frontline patients, and that is ultimately where we want to go. And we think it’s our drug is going to be the ideal drug to combine with the HMA because of all the reasons that Dr. Bejar articulated. But it also will allow us then to decide how to move forward in doublets. So we’re looking at ways to have the VEN/TUS patients for and hopefully we could design it so that we could have an early look at the data accelerated approval as we continue to bring patients on for full approval in a doublet trial. And I’m sure Dr. Bejar can say it far more eloquently. So would you like to jump in? Yeah.
Rafael Bejar: It won’t sound as good as coming from you, Bill, but, I will say that Admiral study’s actually a good model for what you might be able to do in a second line setting. Say for example, with a Tus-venetoclax doublet where you have a study that’s powered to eventually read out overall survival, but that includes an incremental and interim analysis that could be compelling enough to seek approval so that is one option. With the monotherapy study, of course, you don’t have anything compared to. So, we’d just be shooting for a target response rate at that point.
John Newman: Yeah. So thanks for giving us the opportunity to talk about those a little bit, John. Any other questions, John?
Operator: Thank you. I’m currently showing no further questions in the queue. I’d now like to turn the call back over to Dr. Rice for closing remarks.
William Rice: I want to thank everyone for joining us this afternoon, and thank you for all the interest in Aptose, the drugs and the data that we’re generating. We’re gratified as we look in the rear view mirror of 2022. And we see the clinical progress of Tuspetinib and the strides we’re making with the G3 formulation of Lux. Yet our eyes now are really looking forward to 2023 and beyond, and we’re eager to share data with you during the coming year. Again, we talked about being able to present data at the conferences, but also at the earnings calls as well as in as banking meetings. So we want to thank our clinical team, our investigators, our patients for their help and this important work. We appreciate the support of our shareholders and analysts, and we look forward to keeping you updated on our progress the rest of the year. Thank you, and have a good evening.
Operator: Thank you. Ladies and gentlemen, that concludes today’s conference call. You may disconnect and have a wonderful day.
